Compass Therapeutics
CMPX
92 hedge funds and large institutions have $147M invested in Compass Therapeutics in 2024 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 17 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
118% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
16% more funds holding
Funds holding: 79 → 92 (+13)
6.68% more ownership
Funds ownership: 67% → 73.68% (+6.7%)
13% less capital invested
Capital invested by funds: $170M → $147M (-$22.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.79M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.86M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$722K |
| 4 |
SG Americas Securities
New York
|
+$592K |
| 5 |
JP Morgan Chase
New York
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.53M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$3.36M |
| 3 |
Millennium Management
New York
|
-$225K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$159K |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$133K |
CMPX Hedge Fund Activity: Q4 2024 in Review
92 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q4 2024, worth a combined $147M — down 13% from $170M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CMPX positions and 6 closed out — a net gain of 13 holders — while 37 added to existing stakes and 17 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $6.79M. The largest seller was Adage Capital Partners, cutting an estimated $8.53M.
- 92 institutional investors held Compass Therapeutics (CMPX) as of Q4 2024, up from 79 in Q3 2024.
- Funds reported $147M of Compass Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
- 19 funds opened new Compass Therapeutics positions in Q4 2024 and 6 closed out, a net change of +13 holders.
- The largest Compass Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $6.79M added.
- The largest Compass Therapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $8.53M sold.
Based on aggregated 13F filings for Q4 2024.